Love Pharma (CSE: LUV) Investor Presentation



Bring psychedelic therapies and pharmaceutical alternatives to the market

This Love Pharma profile is part of a paid investor education campaign. *


Attitudes towards sexual well-being are changing and the market directly reflects these changes. Sexual well-being is a general term that refers to the physical, mental and social well-being of an individual. This large market is made up of any product related to sexual well-being, such as supplements, contraceptives, lingerie, and other holistic products.

A report by KBV Research estimates that the size of the global sexual well-being market will reach $ 125.1 billion by 2026, with a potential CAGR of 12.4% during this period. This steady growth is due to a renewed interest in sexual discovery, the increasing prevalence of sexually transmitted diseases and the wider shift to electronic commerce.

Love Pharma (CSE: LUV) creates innovative science-driven products to address the ever-changing space of sexual health and wellness. It aims to provide revolutionary products that improve the daily life of the end user by increasing privacy and pleasure. The company was founded in 2020 and is expected to be listed on the Canadian Securities Exchange in 2021, which is subject to regulatory and market approval.

The company’s mission is to provide new and reliable products that use “new age” pharmaceuticals backed by extensive scientific research. Love Pharma will launch products focused on nutraceuticals, which are pharmaceutical alternatives that have natural benefits, such as CBD and THC. It will be launched with two products: Bloom and Auralief. Additional products are already under development.

Bloom is a CBD and / or THC infused arousal gel for female pleasure. According to KBV report, women represent the fastest growing segment of the sexual wellness market. They attribute this trend to an increase in the number of working women as well as greater availability of sex education. While female contraceptives will make up a large part of this growing segment, other products aimed at women may work well. Bloom Awakening Gel has no psychoactive effects and is designed to improve blood circulation, creating physical stimulation with the ultimate goal of increasing pleasure.

In May 2021, Love Pharma partnered with Potent Ventures (OTCMKTS: POTVF) to help launch Love Pharma’s flagship projects in the United States. The US sexual wellness market is expected to reach $ 15.9 billion by 2027, making it a key partnership for the success of Love Pharma’s initial product launch.

Love Pharma Company Highlights

  • Love Pharma specializes in sexual health and wellness by distributing CBD and THC infused products directly to consumers. It holds exclusive licenses to produce, market, package, sell and distribute these patented products in North America, UK and Europe.
  • The company invests in creating long-term sustainable sales through strategic partnerships with distributors
  • Launch products, Bloom and Auralief, are licensed for retail sale, creating immediate revenue opportunity
  • Love Pharma has already planned national and international expansion
  • The management team has an established history of success with cannabis and pharmaceuticals
  • Company plans to create research-backed products that use psychedelics and nutraceuticals
  • Once the company is publicly traded, plans are already in place to quickly distribute products and quickly generate income.

Love Pharma’s key projects


This topical gel is infused with CBD and / or THC for the purpose of increasing blood flow and sensitivity. The product is applied to the vaginal area and rapidly generates blood flow, followed by physical stimulation. The company reports that it has achieved clinical success in increasing the speed of orgasm and the number of orgasms, both of which are important when it comes to physical intimacy.

The initial version of this product to be launched will only contain CBD. Love Pharma has a medical advisor on the company’s product creation side who says CBD improves nerve receptor interaction and blood flow, both of which create more pleasure. Future versions of this product will contain THC.


Auralief is designed to provide relaxation and pain relief. This product is a mucoadhesive strip that applies under the tongue, similar to popular breath-freshening strips. This creates constant contact with this flexible membrane which will allow maximum absorption of the CBD into the product. Auralief is backed by a recent human trial which showed a 30% increase in the effectiveness and speed of performance of both CBD and THC.

Love Pharma management team

Zachary Stadnyk – Director and CEO

Zachary Stadnyk is a corporate finance and advisory professional specializing in the IPO of companies in emerging markets. Stadnyk was head of corporate finance for The Supreme Cannabis Company from 2014-1018, which raised over $ 300,000,000 and was subsequently acquired by Canopy Growth in 2021 for $ 435 million. Stadnyk was the Founder, Director and Chief Executive Officer of DC Acquisition Corp, a capital pool company (“CPC”) which raised an initial amount of $ 3,000,000 when it went public and listed on the Stock Exchange. TSX growth. The issuer completed its qualifying transaction with Kiaro Brands, a major cannabis retailer, in October 2020, which targets sales of $ 50,000,000 in fiscal 2022. Stadnyk also sits on the board of directors of Health Logic Interactive (CHIP – TSXV) device company.

Tatiana Kovaleva – Chief Financial Officer

Tatiana Kovaleva is a Vancouver-based CFO with international and cross-border expertise and credentials as a CPA. Kovaleva has extensive experience in the capital markets, where for over twenty years she held several positions including CFO of publicly traded companies such as M Pharmaceutical Inc. and 360 Blockchain Inc.

Kovaleva has used her leadership experience specializing in public company financial planning and has demonstrated successful experience with timely and accurate financial forecasting, budgeting, reporting and consolidations, as well as IFRS and GAAP accounting.

Joshua Maurice Taylor – Chief Operating Officer

Joshua Maurice has 20 years of consumer goods experience with a focus on over the counter drug and nutraceutical development which includes regulatory clinical research, branding, marketing, advertising and retail distribution. worldwide. He has successfully launched retail brands from concept to retail distribution with direct-to-consumer campaigns as well as physical customers like Walmart, CVS, Target, Walgreens and others. Mauritius’ experience in operations, sales and marketing spans all industries with a focus on profitability and revenue growth.

Douglas Taylor – Director

Douglas Taylor has over 30 years of experience managing projects, services and facilities in the public sector. His previous work included community engagement, strategic planning, business planning and the implementation of a wide range of recreational facilities and services. The implementation included budgeting, financial planning, auditing and human resource management. Taylor’s degree includes two levels of management accounting. He has served on the Glenbriar Board of Directors as CEO for three years and as Chairman for the past two and a half years.

Mark Tommasi – Director

Mark Tommasi has worked as a senior executive, administrator, financier and consultant with over 25 years of experience in business development, private equity, private equity and venture capital, IPOs and private placements, marketing, investor relations, and advisory and committee activities for numerous and private companies (agriculture, technology, junior exploration, and oil and gas) in the United States and Canada. Tommasi is recognized for his ability to help young companies take their business to the next level.

* Disclaimer: This profile is sponsored by Love Pharma (TSX: LUV). This profile provides information sourced from the Investment News Network (INN) and endorsed by Love Pharma to help investors learn more about the company. Love Pharma is an INN client. The company’s campaign costs allow INN to create and update this profile.

INN does not provide investment advice and the information on this profile should not be taken as a recommendation to buy or sell securities. INN does not endorse or recommend the business, products, services or titles of any profiled company.

The information contained herein is for informational purposes only and should not be construed as an offer or solicitation for the sale or purchase of securities. Readers should do their own research for all publicly available information about the company. Before making any investment decisions, readers are recommended to consult Love Pharma directly and seek advice from a qualified investment advisor.



Leave A Reply